Search results
Showing 76 to 90 of 187 results for physiotherapy
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
Early value assessment (EVA) guidance on digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis.
Evidence-based recommendations on minimally invasive total hip replacement. This involves replacing the damaged hip joint (the top part of the upper leg bone and the socket in the hip bone that it fits into) with an artificial one.
View recommendations for HTG236Show all sections
Sections for HTG236
NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant (HTG732)
Evidence-based recommendations on direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant. This involves inserting a metal implant through the skin and into the centre of the bone of the stump and attaching a prosthetic limb to it.
View recommendations for HTG732Show all sections
Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.
to the support or services previously available to them (for example physiotherapy) even when their needs for these services remain...
Why this is important:- There has been debate about the level of physiotherapy needed to preserve lung health since healthcare systems...
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)
Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Nusinersen and risdiplam for treating spinal muscular atrophy (TA1162)
Evidence-based recommendations on nusinersen (Spinraza) and risdiplam (Evrysdi) for treating spinal muscular atrophy.
This quality standard covers assessment, early management and rehabilitation following head injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS74Show all sections
Sections for QS74
- Quality statements
- Quality statement 1: CT head scans
- Quality statement 2: CT head scans for people taking anticoagulants
- Quality statement 3: CT cervical spine scans
- Quality statement 4: Provisional radiology reports
- Quality statement 5: Access to neuroscience units
- Quality statement 6: Inpatient rehabilitation for people with traumatic brain injury
- Quality statement 7: Community rehabilitation services for people with traumatic brain injury